TY  - CONF

T1  - Long-term efficacy and safety data for dupilumab in a phase 3, Open-Label Extension Trial (LIBERTY AD PED-OLE) in patients aged >= 6 to < 12 years with moderate-to-severe atopic dermatitis (AD)

JO  - JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

PY  - 2021/01/01

AU  - Cork MJ

AU  - Thaci D

AU  - Eichenfield L

AU  - Arkwright PD

AU  - Bastian M

AU  - Chen Z

AU  - Delevry D

AU  - O'Malley JT

AU  - Bansal A

ED  - 

VL  - 19

SP  - 14

EP  - 14

Y2  - 2024/12/22

ER  -